ERVMER34 sensitizes the response of HER2 positive breast cancer to neoadjuvant therapy

被引：0
|
作者：
Chi, Y. [1 ]
Ji, W. [1 ]
Xiu, B. [1 ]
Zhang, Q. [1 ]
Wu, J. [1 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P5-03-13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-03-13
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [42] Impacts of HER2 immunohistochemical scores on response and outcomes of HER2-positive breast cancers after neoadjuvant therapy
    Chiu, Yun-Ning
    Hsu, Chih-Yi
    Lien, Pei-Ju
    Chao, Ta-Chung
    Liu, Chun-Yu
    Lin, Yen-Shu
    Wang, Yu-Ling
    Tsai, Yi-Fang
    Tseng, Ling-Ming
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2023, 86 (04) : 409 - 417
  • [43] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    MEDICINE, 2021, 100 (44)
  • [44] Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Melissa Krystel-Whittemore
    Jin Xu
    Edi Brogi
    Katia Ventura
    Sujata Patil
    Dara S. Ross
    Chau Dang
    Mark Robson
    Larry Norton
    Monica Morrow
    Hannah Y. Wen
    Breast Cancer Research and Treatment, 2019, 177 : 61 - 66
  • [45] PREOPERATIVE SYSTEMIC THERAPY FOR HER2 POSITIVE BREAST CANCER
    Ueno, Takayuki
    ANNALS OF ONCOLOGY, 2014, 25
  • [46] Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Krystel-Whittemore, Melissa
    Xu, Jin
    Brogi, Edi
    Ventura, Katia
    Patil, Sujata
    Ross, Dara S.
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Wen, Hannah Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (01) : 61 - 66
  • [47] PREOPERATIVE SYSTEMIC THERAPY FOR HER2 POSITIVE BREAST CANCER
    Ueno, Takayuki
    ANNALS OF ONCOLOGY, 2014, 25
  • [48] THE UPFRONT THERAPY FOR HER2 POSITIVE BREAST CANCER PATIENTS
    Iwata, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 76 - 76
  • [49] HER2 positive breast cancer
    Gianni, Luca
    Bianchini, Giampaolo
    CANCER RESEARCH, 2023, 83 (05)
  • [50] Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer
    Guarneri, Valentina
    Barbieri, Elena
    Piacentini, Federico
    Dieci, Maria Vittoria
    Omarini, Claudia
    Ficarra, Guido
    Bettelli, Stefania Raffaella
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345